Novo Nordisk A/S: Novo Nordisk receives Complete Response Letter in the US for Tresiba(R) and Ryzodeg(R)

Novo Nordisk A/S: Novo Nordisk receives Complete Response Letter in the US for 
Tresiba(R) and Ryzodeg(R) 
BAGSVAERD, DENMARK -- (Marketwire) -- 02/10/13 --  
Company announcement No 11 / 2013: 
http://hugin.info/2013/R/1676898/546736.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: (i) the releases contained herein are protected by copyright and 
other applicable laws; and 
 (ii) they are solely responsible for
the content, accuracy and      originality of the information
contained therein. 
Source: Novo Nordisk A/S via Thomson Reuters ONE
 [HUG#1676898] 
Further information:
Media:
Mike Rulis
+45 3079 3573
mike@novonordisk.com 
Lori Moore
+1 609 919 7991
lrmo@novonordisk.com 
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
krop@novonordisk.com 
Frank Daniel Mersebach
+45 4442 0604
fdni@novonordisk.com 
Lars Borup Jacobsen
+45 3075 3479
lbpj@novonordisk.com 
Jannick Lindegaard (US)
+1 609 786 4575
jlis@novonordisk.com